Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10

The Company Will Host a Conference Call at 8:30am ET

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on Thursday, May 10, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss first quarter financial results.

Conference Call Dial-In Information:

        
        
        
        
        
        
        
      
      
        
          Participant Toll-Free Dial-In Number:
        
        
        
        
        
        
          [phone]
        
      
      
        
          Participant International Dial-In Number:
        
        
        
        
        
        
          [phone]
        
      
      
        
          Pass Code:
        
        
        
        
        
        
          2192025
        
      
      
        
        
        
        
        
        
        
           
        
      
    
    

Please specify to the operator that you would like to join the “Catabasis First Quarter 2018 Results Call.”

Interested parties may access a live audio webcast of the conference call via the investor section of the Catabasis website, www.catabasis.com. Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.

About CatabasisAt Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. Our lead program in development is edasalonexent for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our pipeline of drug candidates, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180503005250/en/

Investor and Media ContactCatabasis Pharmaceuticals, Inc.Andrea Matthews, [e-mail]